S-1/A: Kindly MD Outlines Executive Compensation and Governance in New Filing

Kindly MD details executive employment agreements, including compensation, responsibilities, and termination conditions, alongside corporate governance and legal considerations in a recent SEC filing.

Summary

• Kindly MD has filed an employment agreement outlining the terms of engagement for its Chief Operating Officer, Adam Cox.
• The agreement, effective May 1st, 2022, and executed December 30, 2022, details Cox's responsibilities, compensation, and conditions for termination.
• Cox's initial annual salary is set at $138,000, with a minimum 2% annual increase.
• Upon successful completion of a $6 million corporate fundraising, the salary will increase to $224,000.
• Cox received 34,992 fully vested shares of restricted common stock and is slated to receive an additional 75,000 shares of restricted common stock.
• These additional shares vest upon milestones such as completing a $6 million fundraising (35,000 shares) and years of continuous employment (10,000 shares per year).
• The agreement includes non-competition and non-solicitation clauses extending one year post-employment.
• It also covers confidentiality, HIPAA compliance, and intellectual property rights.
• The document outlines conditions for termination, including death, disability, cause, or good reason, and specifies obligations of the company upon termination.
• The filing also includes an S-1/A registration statement updated to include restated audited financial statements for the year ended December 31, 2023, with details on the restatement in Note 2.
• The company is planning an initial public offering of 1,272,727 Units, each consisting of one share of common stock, one tradeable warrant, and one non-tradeable warrant.
• The initial public offering price is $5.50 per Unit.
• Certain selling stockholders may also resell up to 1,712,057 shares of common stock.
• The document highlights risks associated with the offering, including potential price volatility and control by the majority shareholder.

Sentiment

Score: 6

Explanation: The document is a mix of positive and negative elements. The executive employment agreement is generally positive for the executive, while the IPO and risk disclosures introduce uncertainty. The restatement of financial statements is a neutral to slightly negative factor.

Positives

• The employment agreement incentivizes the COO with salary increases and stock vesting tied to company milestones.
• The company is pursuing an IPO to raise capital.
• The company is addressing the opioid crisis with alternative treatments and data collection.

Negatives

• The company is subject to non-competition and non-solicitation clauses.
• The company is loss making.
• The company is subject to the risks of the cannabis industry.

Risks

• The company's operations, although compliant with Utah state law, are still subject to U.S. federal law which classifies cannabis as a Schedule I controlled substance.
• There is always a risk of federal enforcement action, and non-compliance could lead to significant legal penalties, including but not limited to fines, imprisonment, seizure of assets, and prohibition of business operations.
• The company may need additional capital that will dilute the ownership interest of investors.
• The company will be controlled by its existing majority shareholder.
• Holders of the Warrants will have no rights as a holder of our Common Stock until they acquire our Common Stock.
• Unless the Company becomes public and an active trading market develops for our securities, investors may not be able to sell their shares.
• Costs and expenses of being a reporting company under the 1934 Securities Exchange Act may be burdensome and prevent us from achieving profitability.

Future Outlook

The company intends to use the net proceeds of this offering primarily for general corporate purposes, including capital expenditures, labor, real estate, marketing and sales, technology development, and other expenses.

Industry Context

The document reflects the growing trend of integrating behavioral health with traditional medical practices, particularly in pain management, and the increasing interest in alternative medicine.

Comparison to Industry Standards

• The executive compensation package appears competitive with similar roles in healthcare companies of comparable size.
• The non-compete and non-solicitation clauses are standard practice in executive employment agreements to protect company interests.
• The focus on HIPAA compliance and data security aligns with industry best practices for healthcare providers.
• The company's efforts to address the opioid crisis and promote alternative treatments are in line with current public health initiatives.

Stakeholder Impact

• Shareholders: Potential dilution from the IPO and future equity issuances.
• Employees: Job security and compensation terms outlined in the employment agreement.
• Customers: Continued access to healthcare services and alternative treatments.
• Creditors: Repayment of existing debt and potential for future financing.

Next Steps

• Complete the initial public offering.
• Achieve the $6 million fundraising milestone to trigger salary and stock vesting for the COO.
• Comply with ongoing reporting requirements as a public company.
• Execute the company's growth strategy, including potential acquisitions and expansion.

Key Dates

Keywords

employment agreement, restricted stock, fundraising, non-competition, non-solicitation, confidentiality, HIPAA, intellectual property, termination, initial public offering, common stock, warrants, risk factors, Kindly MD, Adam Cox